Form 4: Athira Pharma Executive San Martin Acquires Stock Options and Restricted Stock Units

Chief Medical Officer Javier San Martin acquired stock options and restricted stock units in Athira Pharma, according to a recent SEC filing.

Summary

• Javier San Martin, Chief Medical Officer of Athira Pharma, acquired 111,270 stock options and 74,180 restricted stock units (RSUs) on March 3, 2025.
• The stock options have an exercise price of $0.3762 and vest monthly over 48 months, expiring on March 2, 2035.
• The RSUs vest 100% on the one-year anniversary of the grant date.
• Following these transactions, San Martin directly owns 111,270 stock options and 74,180 RSUs.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting insider transactions. The sentiment is neither particularly positive nor negative.

Positives

• The acquisition of stock options and RSUs by a key executive like the Chief Medical Officer can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency into the equity ownership of company executives.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the executive.

Key Dates